Theriva Biologics, Inc.
New York Stock Exchange AmericanTotal Valuation
Theriva Biologics, Inc. carries a market capitalization of 8.21M, placing it among publicly traded companies globally. Its enterprise value stands at -6.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.21M |
| Enterprise Value | -6.99M |
Share Statistics
Theriva Biologics, Inc. currently has 45.89M shares outstanding.
| Shares Outstanding | 45.89M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 12.51, and the price-to-book ratio stands at -0.01.
| PE Ratio | N/A |
| PS Ratio | 12.51 |
| PB Ratio | -0.01 |
| P/TBV Ratio | -0.98 |
| P/FCF Ratio | -0.26 |
| P/OCF Ratio | -0.26 |
Financial Position
Theriva Biologics, Inc. maintains a current ratio of 1.63, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.63 |
| Quick Ratio | 1.58 |
| Debt / Equity | 23.98 |
| Debt / EBITDA | -0.17 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -60.96 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Theriva Biologics, Inc.'s stock has declined approximately -52.32172% over the past 52 weeks. The 50-day moving average sits at 0.27, while the 200-day moving average is 0.26.
| Beta (5Y) | N/A |
| 52-Week Price Change | -52.32172% |
| 50-Day Moving Average | 0.27 |
| 200-Day Moving Average | 0.26 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Theriva Biologics, Inc. generated 300,000.00 in revenue and converted that into -21.46M in net income, yielding earnings per share of -1.12. EBITDA reached -21.66M, while operating income came in at -21.76M.
| Revenue | 300,000.00 |
| Gross Profit | N/A |
| Operating Income | -21.76M |
| Pretax Income | -21.46M |
| Net Income | -21.46M |
| EBITDA | -21.66M |
| EBIT | -21.76M |
| Earnings Per Share (EPS) | -1.12 |
Balance Sheet
Theriva Biologics, Inc. holds 14.43M in cash and equivalents against 3.69M in total debt, resulting in a net debt position of -12.77M. Total book value stands at -360.71M, with working capital of 6.49M providing operational flexibility.
| Cash & Cash Equivalents | 14.43M |
| Total Debt | 3.69M |
| Net Debt | -12.77M |
| Equity (Book Value) | -360.71M |
| Book Value Per Share | -18.82 |
| Working Capital | 6.49M |
Cash Flow
Theriva Biologics, Inc. produced -14.37M in operating cash flow over the past twelve months. After subtracting -19,000.00 in capital expenditures, free cash flow totaled -14.39M - equivalent to -0.75 per share.
| Operating Cash Flow | -14.37M |
| Capital Expenditures | -19,000.00 |
| Free Cash Flow | -14.39M |
| FCF Per Share | -0.75 |
Margins
Theriva Biologics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -7,254.00 and net profit margin of -7,153.00 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -7,254.00 |
| Pretax Margin | -7,153.00 |
| Profit Margin | -7,153.00 |
| EBITDA Margin | -7,218.67 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -505.92 |
| FCF Yield | -382.36 |
Stock Splits
Theriva Biologics, Inc.'s most recent stock split took place on August 26, 2024 with a 25:1 split ratio.
| Last Split Date | 8/26/2024 |
| Split Ratio | 25:1 |
Scores
Theriva Biologics, Inc. posts an Altman Z-Score of -29.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -29.80 |